- Home
- AVDX vs AGIO Comparison
AVDX vs AGIO Comparison
Compare AVDX & AGIO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- AVDX
- AGIO
- Stock Information
- Founded
- AVDX 2000
- AGIO 2007
- Country
- AVDX United States
- AGIO United States
- Employees
- AVDX N/A
- AGIO N/A
- Industry
- AVDX EDP Services
- AGIO Biotechnology: Pharmaceutical Preparations
- Sector
- AVDX Technology
- AGIO Health Care
- Exchange
- AVDX Nasdaq
- AGIO Nasdaq
- Market Cap
- AVDX 2.1B
- AGIO 2.3B
- IPO Year
- AVDX 2021
- AGIO 2013
- Fundamental
- Price
- AVDX $9.93
- AGIO $36.78
- Analyst Decision
- AVDX Hold
- AGIO Buy
- Analyst Count
- AVDX 14
- AGIO 6
- Target Price
- AVDX $9.73
- AGIO $57.00
- AVG Volume (30 Days)
- AVDX 1.7M
- AGIO 779.8K
- Earning Date
- AVDX 11-05-2025
- AGIO 10-30-2025
- Dividend Yield
- AVDX N/A
- AGIO N/A
- EPS Growth
- AVDX N/A
- AGIO N/A
- EPS
- AVDX N/A
- AGIO 11.13
- Revenue
- AVDX $446,722,000.00
- AGIO $40,875,000.00
- Revenue This Year
- AVDX $5.58
- AGIO $28.19
- Revenue Next Year
- AVDX $9.73
- AGIO $152.14
- P/E Ratio
- AVDX N/A
- AGIO $3.31
- Revenue Growth
- AVDX 8.04
- AGIO 30.57
- 52 Week Low
- AVDX $6.61
- AGIO $23.42
- 52 Week High
- AVDX $11.68
- AGIO $62.58
- Technical
- Relative Strength Index (RSI)
- AVDX 59.09
- AGIO 48.43
- Support Level
- AVDX $9.93
- AGIO $34.97
- Resistance Level
- AVDX $9.95
- AGIO $37.91
- Average True Range (ATR)
- AVDX 0.01
- AGIO 1.67
- MACD
- AVDX -0.00
- AGIO -0.21
- Stochastic Oscillator
- AVDX 50.00
- AGIO 48.57
About AVDX AvidXchange Holdings Inc.
AvidXchange Holdings Inc is a provider of AP automation software and payment solutions for middle-market businesses and their suppliers. It generates the majority of its sales from Payment revenue followed by Software revenue and Services revenue. The company generates revenue in the United States.
About AGIO Agios Pharmaceuticals Inc.
Agios Pharmaceuticals Inc is a biopharmaceutical company focused on the field of cellular metabolism to create differentiated medicines for rare diseases, with a focus on classical hematology. The company's primary focus is to develop potentially transformative small-molecule medicines. Its product candidate, Pyrukynd (mitapivat), is an activator of both wild-type and mutant pyruvate kinase enzymes, developed for the treatment of hemolytic anemias. The other drug candidates in its pipeline include Tebapivat (PK activator), being developed as a potential treatment for MDS-associated anemia and sickle cell disease, AG-181 (PAH stabilizer), AG-236, and others.